Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of glp-1 capsule in China. Welcome to wholesale bulk high quality glp-1 capsule for sale here from our factory. Good service and reasonable price are available.
GLP-1 capsule is an intestinal insulinotropic hormone secreted by intestinal L cells, whose core function is to regulate energy metabolism through a "glucose dependent" mechanism. The capsule contains artificially synthesized GLP1 receptor agonists (such as oral formulations of semaglutide and liraglutide), which activate the systemic GLP1 receptors by simulating the action of natural GLP1, achieving blood glucose control, appetite suppression, and energy consumption optimization. Some capsules are extracted from plant extracts such as IGOB131 ®, Cinnamaldehyde or probiotic ingredients (such as strains containing P9 protein) stimulate intestinal L cells to secrete more endogenous GLP1, forming an "autologous hormone regulation cycle" and enhancing the sustainability of metabolic regulation.
The core pathology of type 2 diabetes is insulin resistance and beta cell failure, which leads to imbalance of energy distribution: reduced glucose uptake by muscle and adipose tissue, increased gluconeogenesis in liver, and increased glucose and free fatty acid (FFA) levels in blood. GLP1 receptor agonists promote insulin synthesis through the cAMP PKA pathway, while inhibiting beta cell apoptosis. They also reduce hepatic glucose output by decreasing hepatic FFA uptake and the expression of key gluconeogenesis enzymes such as PEPCK and G6Pase, while promoting hepatic sensitivity to insulin, transforming the liver from an "energy output organ" to an "energy storage organ". By activating the AMPK pathway, they promote glucose uptake and glycogen synthesis in muscle tissue, increase mitochondrial oxidative phosphorylation (OXPHOS) efficiency, reduce lactate production, and achieve "maximum energy utilization".
|
|
|
GLP-1 COA
The mechanism and reaction mode of this drug
GLP-1 capsule (glucagon like peptide-1) receptor agonists play an important role in the treatment of diabetes and obesity, and their capsule formulations are widely concerned by virtue of oral convenience. However, like all drugs, GLP1 capsules may also trigger a series of adverse reactions while exerting therapeutic effects.
Acting on the gastrointestinal tract
Gastrointestinal reactions are the most common adverse reactions of GLP1 capsules, and their mechanism of occurrence is closely related to the widespread distribution of GLP1 receptors in the gastrointestinal tract. GLP1 receptor agonists act by binding to GLP1 receptors in the gastrointestinal tract, delaying gastric emptying, increasing satiety, and reducing food intake. However, this process may also cause a series of gastrointestinal discomfort symptoms.
Nausea: Nausea is one of the most common gastrointestinal reactions in the early stages of GLP1 capsule treatment. Its incidence is relatively high, especially in the early stages of medication, and some patients may experience mild to moderate nausea due to the high sensitivity of the gastrointestinal tract to drugs. Nausea symptoms usually appear within hours to days after medication, and as the medication time prolongs, most patients' nausea symptoms will gradually alleviate or disappear. However, for a small number of patients, nausea symptoms may persist and even affect their daily life and medication adherence.
Vomiting: Vomiting is a further development of nausea, and when nausea symptoms are more severe, patients may experience vomiting. The occurrence of vomiting not only brings physical discomfort to patients, but may also lead to serious consequences such as electrolyte imbalance and dehydration. Therefore, patients who experience vomiting symptoms should seek medical attention promptly, assess their condition, and take appropriate treatment measures.
Dysdigestion: Dysdigestion is characterized by discomfort in the upper abdomen, a feeling of fullness, belching, and other symptoms. GLP1 capsules may cause indigestion by affecting gastrointestinal motility and secretion of digestive fluids, leading to poor food digestion and absorption. Symptoms of indigestion usually appear in the early stages of medication, and with the prolongation of medication time, most patients' symptoms will gradually improve.
Abdominal pain: Some patients may experience abdominal pain symptoms during the use of GLP1 capsules. Abdominal pain may manifest in different forms such as dull pain, bloating, or cramping, and its mechanism of occurrence may be related to the effect of drugs on gastrointestinal smooth muscle. Abdominal pain symptoms are usually mild, but a few patients may experience severe abdominal pain and need to seek medical attention promptly to investigate other causes.
Preventive and treatment measures
Starting from a small dose and gradually increasing the dose
Gradual dose escalation enables gastrointestinal adaptation.
Adjusting dietary structure
Patients are advised to take light meals and skip greasy, spicy food to ease GI irritation.
Split eating
Frequent small meals instead of three large ones ease gastrointestinal load and relieve digestive discomfort.
Symptomatic treatment
Severe GI adverse reactions require doctor-supervised antiemetic or antidiarrheal medication.
Metabolism and endocrine response
GLP-1 capsule, as hypoglycemic drugs, have metabolic and endocrine reactions mainly involving hypoglycemia and thyroid dysfunction.Hypoglycemia: GLP1 receptor agonists are blood glucose concentration dependent hypoglycemic drugs, and their hypoglycemic effects are closely related to the blood glucose concentration in the patient's body. When blood sugar decreases, the effect of GLP1 receptor agonists will correspondingly weaken, so the risk of hypoglycemia is lower when using GLP-1 alone.
However, when GLP-1 are used in combination with other hypoglycemic drugs such as insulin, sulfonylureas, etc., the risk of hypoglycemia may increase. Symptoms of hypoglycemia include palpitations, sweating, hand tremors, hunger, etc. In severe cases, coma or even life-threatening situations may occur.
Preventive and treatment measures
Strengthen blood glucose monitoring:
Enhance blood glucose monitoring during GLP1 capsule therapy, especially with other antidiabetics, to spot and manage hypoglycemia timely.
Adjust medication dosage:
Based on blood glucose monitoring results, adjust medication dosage in a timely manner under the guidance of a doctor to avoid the occurrence of hypoglycemia.
Carry sugar cubes or sugary drinks with you
Hypoglycemia-prone patients should carry candies or sweet drinks for urgent glucose supplementation when symptoms arise.
Thyroid dysfunction: GLP-1 receptor agonists may have certain effects on thyroid function, especially the risk of medullary thyroid cancer. Research has shown that GLP-1 receptor agonists can promote the formation of cyclic adenosine monophosphate in thyroid C cells, increasing serum calcitonin synthesis and release, which may lead to the occurrence of thyroid C cell carcinoma. However, the causal relationship between GLP-1 receptor agonists and medullary thyroid cancer is not yet fully understood. For safety reasons, patients with a personal or family history of medullary thyroid cancer should use GLP-1 with caution.
Preventive and treatment measures
Detailed medical history inquiry
Before using GLP1 capsules, doctors should inquire in detail about the patient's thyroid disease history and family history to assess the risk of medication use.
Regular monitoring of thyroid function
GLP‑1 capsule users need regular thyroid function checks to detect and manage thyroid disorders early.
Acting on the cardiovascular system
GLP-1 may have certain effects on the cardiovascular system, mainly manifested as increased heart rate and changes in blood pressure.Heart rate increase: The use of GLP-1 receptor agonists can cause an increase in heart rate in patients, and the magnitude of the increase in heart rate is related to the duration of GLP-1 action. Short acting GLP-1 receptor agonists may cause a brief increase in heart rate, while some long-acting GLP-1 receptor agonists may cause a sustained increase in circadian heart rate. An increase in heart rate may lead to discomfort symptoms such as palpitations and chest tightness, which may increase the risk of cardiovascular events for patients with pre-existing cardiovascular diseases.
Preventive and treatment measures:Monitoring heart rate changes: During the use of GLP-1, patients should regularly monitor heart rate changes, promptly detect heart rate abnormalities, and take corresponding measures.Symptomatic treatment: For patients with significant increase in heart rate, appropriate use of heart rate regulating drugs (such as beta blockers) can be administered under the guidance of a doctor for symptomatic treatment.Blood pressure changes: The effect of GLP-1 receptor agonists on blood pressure is still controversial.
Some studies suggest that GLP-1 receptor agonists may have a mild antihypertensive effect, while others have not found a significant impact on blood pressure.However, for patients with pre-existing hypertension, it is still necessary to closely monitor blood pressure changes when using GLP-1 to avoid excessive blood pressure fluctuations that may cause cardiovascular events.
Preventive and treatment measures:Regular monitoring of blood pressure: During the use of GLP-1 , patients should regularly monitor blood pressure changes, promptly detect blood pressure abnormalities, and take corresponding measures.Adjusting the dosage of antihypertensive drugs: For patients with pre-existing hypertension, it may be necessary to adjust the dosage of antihypertensive drugs in a timely manner under the guidance of a doctor based on blood pressure monitoring results when using GLP-1 drug.
The advantage is that it acts on the nerves
GLP1 drug may have certain effects on the nervous system, mainly manifested as symptoms such as headache and dizziness. These symptoms are usually mild, but a few patients may experience severe headaches or dizziness, affecting their daily life and work.
Rest adjustment: While receiving GLP‑1 capsule treatment, patients ought to maintain adequate rest, steer clear of physical exhaustion and prolonged mental strain, which effectively lowers the risk and severity of nerve-related side effects. Symptomatic intervention: Those troubled with refractory severe headache or pronounced dizziness may receive prescription analgesics or anti-vertigo agents under professional medical supervision for targeted symptomatic relief.
References
He Liyun, Zhang Huabing, Li Yuxiu. Comprehensive evaluation and rational decision-making: the latest findings on the risk of using glucagon like peptide-1 receptor agonists [J]. Peking Union Medical Journal, 2022, 13 (6): 948-952
Sattar N, Lee M M Y, Kristensen S L, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials[J].The Lancet Diabetes & Endocrinology,2021,9(8):653-662.
Endocrinology Branch of Chinese Medical Association. Expert consensus on clinical application of glucagon like peptide-1 receptor agonist in the treatment of type 2 diabetes [J]. Chinese Journal of Internal Medicine, 2020,59 (11): 836-846
Glucagon-like Peptide-1 Protects Mesenteric Endothelium from Injury During Inflammation(https://pmc.ncbi.nlm.nih.gov/articles/PMC2954434/)
Efficient GLP-1 gene delivery using two-step transcription amplification plasmid system with a secretion signal peptide and arginine-grafted bioreducible polymer(https://pmc.ncbi.nlm.nih.gov/articles/PMC3248954/)
FAQ
Q: What is Foreign Trade-Express?
A: FAQ1: What core physiological mechanisms enable GLP-1 to lower blood glucose and control body weight simultaneously?
GLP-1 is an endogenous incretin peptide secreted from intestinal L-cells after food intake, exerting glucose-dependent hypoglycemic regulation without triggering hypoglycemia risk under normal low-sugar status. On glycemic control, it selectively boosts insulin synthesis and secretion from pancreatic β-cells when blood glucose rises, meanwhile restraining excessive glucagon release from α-cells to cut hepatic glucose overproduction, and protects islet cells against inflammatory apoptosis to preserve long-term pancreatic function. For weight management, GLP-1 binds central GLP-1 receptors inside hypothalamus to enhance satiety signal, delays gastric emptying and gastrointestinal peristalsis to prolong stomach fullness, naturally reducing daily food intake and cumulative calorie surplus; multi-organ synergism makes dual regulation on glycemia and body weight achievable.
Q: What are the most common adverse reactions of GLP-1 receptor agonists, and how do these side effects change during continuous medication?
A: Gastrointestinal discomfort stands as the dominant adverse response of GLP-1 agonists, including mild nausea, transient vomiting, bloating, diarrhea or constipation, which mostly emerge within the initial 2–8 weeks of administration as the gastrointestinal tract adapts to delayed emptying effects. Such mild symptoms usually alleviate spontaneously with gradual dose titration and sustained medication for 1–3 months without permanent drug withdrawal needed. Severe adverse events remain rare in clinical practice: sporadic acute pancreatitis, gallbladder-related discomfort or injection-site redness only happen in individual susceptible populations; patients with family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 need to avoid GLP-1 products entirely for safety concerns.
Q: Besides type 2 diabetes and obesity, what emerging clinical application directions are being verified for GLP-1-related peptides in current research?
A: Growing preclinical and clinical trials confirm GLP-1 agonists possess multi-organ protective effects beyond metabolic regulation, expanding their therapeutic boundary steadily. In cardiovascular field, long-acting GLP-1 analogs reduce major adverse cardiovascular events such as myocardial infarction and stroke via improving vascular endothelial function, lowering chronic inflammation and blood lipid levels, already recommended for diabetic patients complicated with cardiovascular risks by global clinical guidelines. Hepatic research focuses on non-alcoholic fatty liver disease; GLP-1 can mitigate hepatic steatosis and liver inflammatory injury by regulating intrahepatic lipid metabolism. Meanwhile, multiple ongoing studies explore its neuroprotective potential for Alzheimer's disease and ischemic stroke, relying on anti-inflammatory and nerve-cell anti-apoptosis properties to slow neurodegenerative progression.
Hot Tags: glp-1 capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale